CARGO Therapeutics Common Stock (CRGX)

CARGO Therapeutics, Inc., traded on the NASDAQ under the ticker symbol CRGX, is a promising biotech company focused on developing cutting-edge treatments for cancer patients.
CARGO's primary focus is on creating innovative chimeric antigen receptor (CAR) T-cell therapies known for their potential in targeting cancer effectively.

One of CARGO's flagship projects is the CRG-022, a personalized CD22 CAR T-cell therapy specifically designed to combat resistance mechanisms in B-cell malignancies. This therapy aims to target an alternative tumor antigen, CD22, to enhance its effectiveness in treating cancer.

In addition, CARGO is also in the process of developing CRG-023, a novel tri-specific CAR T-cell therapy that targets tumor cells expressing three different B-cell antigens. This multifaceted approach demonstrates the company's commitment to exploring diverse treatment options for cancer patients.

Founded in 2019 and headquartered in San Mateo, California, CARGO Therapeutics, Inc. was formerly known as Syncopation Life Sciences, Inc. before rebranding itself in September 2022. Their dedication to advancing cancer treatment can be explored further on their website at https://cargo-tx.com.